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Abstract 
Background: The growing threat of insecticide resistance in mosquitoes and drug resistance in the Plasmodium 
parasites increases the importance of ensuring appropriate malaria case management and enabling positive health‑
seeking behaviour. Treatment‑seeking behaviours are poorly characterized in malaria‑endemic regions that have been 
the focus of intensive control and elimination campaigns. This study uses a comprehensive approach to shed light on 
the determinants of malaria treatment‑seeking behaviours from different perspectives.
Methods: The authors conducted cross‑sectional surveys from 832 households, fifteen health centers, and 135 
retailers across three sites in the Emuhaya and Kakamega districts of the western Kenyan highlands. Participants were 
recruited via random sampling and data were collected with the use of a structured questionnaire about malaria 
treatment‑seeking behaviour. All households, healthcare facilities, and retailers were mapped using a handheld GPS 
and a GIS algorithm was used to calculate “walk distance” based on the Tobler rule; an estimate of this distance was 
used to calculate the travel time used in the analyses.
Results: Across the three sites, 47.5–78.9 % of the residents sought diagnosis and treatment at hospitals, clinics, or 
dispensaries; 6.3–26.1 % of the residents sought malaria care only at pharmaceutical retailers. Overall, 40.3–59.4 % of 
residents reported delaying seeking care for more than 24 h after fever onset. After adjustment, residents who chose 
to visit a pharmaceutical retail facility rather than a hospital were 121 and 307 % more likely to delay seeking medical 
care after fever onset than those who reported choosing a healthcare facility for treatment. No significant association 
was found between travel time and delay in seeking care. The surveys of the healthcare facilities indicated an average 
total cost per patient per visit was 112 KES ($1.40 US) for public facilities and 165 KES ($2.06 US) for private facilities.
Conclusion: Understanding the local health behaviours that perpetuate transmission of malaria will help develop 
targeted preventive measures and educational interventions that can empower the residents with the knowledge 
needed to combat malaria in a safe and effective manner. Ensuring patient access to health care facilities in coun‑
tries with high disease burdens has broader implications on measures of equity and on public health prevention 
methodologies.
© 2016 Dixit et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
In spite of intensified malaria control efforts, malaria is a 
major public health problem, particularly in Africa. Glob-
ally, malaria is estimated to affect 200 million people and 
kill more than 500,000 people per year, mostly children 
under the age of five [1]. In the past decade, Africa has 
seen a vast increase in coverage with vector control inter-
ventions, with almost half of the susceptible population 
receiving access to insecticide-treated bed nets [1]. Addi-
tionally, indoor residual spraying in Africa protected over 
55 million people from malaria [1]. However, with the 
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growing threat of insecticide resistance in mosquitoes 
[2, 3] and drug resistance in the parasites [4, 5], ensuring 
appropriate malaria case management and enabling posi-
tive health-seeking behaviour grows in importance.
The health behaviours of the local populace are intrin-
sically linked to case management policies. Sensitive and 
accurate diagnosis and timely treatment with effective 
drugs are key components of the World Health Organiza-
tion (WHO) malaria treatment guidelines [6]. However, 
without an understanding of the treatment-seeking behav-
iours of the susceptible population as well as a careful 
evaluation of the determining factors of those behaviours, 
malaria control and elimination programmes may be frag-
mented from the reality seen in the field, and consequently 
intervention strategies may not be effective or sustainable.
An important variable in the determination of health-
seeking behaviour is access to health care services. 
According to the WHO, people living within 1  h of 
travel time of a health care facility are generally consid-
ered to have access to health care [7]. The inverse rela-
tionship between distance to facility and use of health 
care services has been well established [8–10]. However, 
it has largely been based on measures of Euclidean dis-
tance [7] even when the topography and transport infra-
structure in the area rarely allow for a direct path to the 
facility. In addition to travel impedances, other factors 
that can affect health-seeking behaviour include afford-
ability and availability of medicines and medical care 
[11]. Previous studies have shown that in the absence of 
access to trained medical personnel, people will choose 
to receive information from untrained sources such as 
the local chemist or pharmaceutical retailer [12, 13]. Self-
medication or home treatment of malaria has generally 
been shown to have a lower cure rate than treatment 
in an institutional setting [14] and the tendency to self-
diagnose malaria and subsequently self-medicate, has 
been growing in regions of Africa with limited healthcare 
access [15, 16]. These various factors all have an impact 
on the perpetuation of regional malaria transmission.
In Kenya, 76 % of the population is at risk for malaria; 
in 2013, there were over 2.3 million confirmed cases of 
malaria in the country [1]. It is crucial to ensure that peo-
ple are seeking appropriate diagnosis and anti-malarial 
treatment in a timely manner to reduce malaria mortal-
ity, morbidity, and transmission. As treatment-seeking 
behaviour and healthcare utilization has been shown to 
be affected by the multitude of factors listed above, we 
attempted to exact a more comprehensive measure by 
integrating opinions and habitudes from consumers, 
health providers, and retailers. The holistic nature of the 
study is especially appropriate at a time where malaria 
control efforts such as mass distributions of bed nets 
and subsidy of artemisinin-based combination therapy 
(ACT) have intensified, but without a suitable adjust-
ment for health-seeking behaviour patterns of the study 
population.
The objective of this study was to determine the malaria 
treatment-seeking behaviour patterns in the western 
Kenya highlands, and to elucidate some of the major per-
ceived hindrances to healthcare access in that region. The 
residents’ perceptions regarding barriers may impinge 
upon their ability to seek diagnoses and treatment at a 
healthcare facility in a timely manner. This discordance 
between perceptions and reality may serve as a critical 
target point in an effective malaria control or elimination 
programme.
Ethical considerations
The project was approved by the Institutional Review 
Board of UC-Irvine and Ethical Review Committee of 
Kenya Medical Research Institute.
Methods
Study area and study population
The authors conducted cross-sectional surveys in three 
study sites, and data were collected from 832 households, 
15 health centres, and 135 retailers in the Emuhaya and 
Kakamega districts in the western Kenyan highlands 
(Fig.  1a). The study sites included three sub-locations: 
Iguhu (34˚44′E, 0˚11′N, 1430–1580  m above sea level) 
in Kakamega district (Fig.  1b); and Emakakha (34˚39′E, 
0˚07′N, 1460–1520  m above sea level) (Fig.  1c) and 
Emutete (34˚38′E, 0˚02′N, 1480–1640 m above sea level) 
(Fig. 1d) in Emuhaya district. Each site was 3 × 6 km2 and 
each was composed of several villages. These sites were 
used for other vector ecology and malaria epidemiology 
research by other members of the research team [17–19]. 
The topography of the study area consists of hills, valleys, 
and plateaus and a variety of land use and land cover pat-
terns exist. This region generally experiences two rainy 
seasons (April–May and October–November) and two 
dry seasons (January–February and July–August) [13] 
although during the year the survey was conducted, the 
rainy season started later than in previous years and 
lasted well into August 2011 [6, 14].
Local resident survey
In each of the three study sites, the questionnaire was 
administered to an adult member of the randomly 
selected households. Informed consent was obtained 
from every participant in the study. All households were 
mapped using handheld global positioning systems (GPS) 
(Garmin). The predominant tribe in the area is the Luhya 
tribe and thus, all surveys were translated from Eng-
lish and orally administered in the Luhya language. Sur-
vey questions were used to acquire demographic and 
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socioeconomic information and to determine the par-
ticipants’ treatment-seeking behaviour with regards to 
malaria. The survey also included questions pertaining 
to treatment facility choices and treatment affordability. 
All options were read out to the respondents before their 
answer was recorded. The surveys were conducted by 
local, trained technicians, over a period of several months, 
beginning in mid-July and ending in mid-December.
Health facility survey
To assess coverage and utilization of health facilities by 
local residents, all healthcare facilities within the three 
study areas were mapped and surveyed by field staff. 
The initial step was to acquire the complete list of health 
facilities from KEMRI (Kenya Medical Research Insti-
tute). The list contained records of more than 100 facili-
ties in the Western Province with information on services 
offered, the approximate location, and the second to fifth 
administrative level in which each facility was located. 
Second, each health facility on the topographic map from 
Kenya Geological Survey was located and health facilities 
that fell within a ten kilometer radius of the study area 
and were thus, most likely to serve potential study par-
ticipants were selected; there were fifteen health facilities 
on the final list. The team visited each health facility on 
the final list, recorded the facility’s GPS coordinates, and 
administered the questionnaire to the medical staff mem-
ber in charge. The information acquired included hours 
and days of operation, the number and type of medical 
staff, malaria diagnosis method, any facility-imposed 
charges associated with a suspected malaria visit, and the 
storage and supply of anti-malarials.
Pharmaceutical retail facility survey
Given that a considerable proportion of residents pur-
chase anti-malarials from pharmaceutical retail facilities, 
Fig. 1 a Overview of all study sites. Location of study sites within Kenya. b, c, d Iguhu, Emakakha, and Emutete study areas. Each map focuses on 
the individual study area and shows the distribution of residents’ healthcare seeking patterns. The individual study area’s healthcare facilities and 
retail outlets are also shown along with its roads and access paths
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it is necessary to include such facilities in the surveil-
lance. The team searched for and interviewed all poten-
tial outlets along roads and markets where retail facilities 
are normally located. Pharmaceutical retail facility own-
ers were asked to respond to questions regarding the 
presence of a licensed pharmacist on site, approximate 
number of customers served per day, types of anti-malar-
ials in stock, cost for anti-malarials and their supplier for 
the medication. A total of 135 retailers were surveyed. A 
small, random sample of these outlets (eight in total) was 
chosen and one prescription of artemether-lumefantrine 
(AL, Coartem®) was purchased from each of the chosen 
outlets in the sample to test for the levels and presence 
of the pharmacologically relevant active compound by 
means of ELISA and HPLC [20, 21]. The tests were per-
formed according to the protocols described by Wang 
et al. [21].
Data analysis
A total of 832 households, 15 healthcare facilities, and 
135 pharmaceutical retail facilities across three study 
sites participated in the study. All survey responses were 
entered into MS Excel and the coordinates from the GPS 
readings were transferred to ArcGIS 10.2 to generate 
the necessary maps (Fig.  1). A GIS algorithm to calcu-
late “walk distance” was created based on the Tobler rule 
[22]. The estimate of this distance was used to calculate 
the travel time used in the remaining analyses. For more 
information, please refer to Additional file 1.
One of the major purposes of the survey was to deter-
mine whether or not the participants sought diagnosis 
and treatment within 24 h of fever onset. Logistic regres-
sion was performed on the individual  survey data using 
the likelihood of delay as the binary outcome variable. 
The outcome of a delay in seeking diagnosis and treat-
ment was regressed on key sociodemographic and health-
seeking behaviour variables, both individually and in 
combination. The results of the bivariate analyses and an 
adjusted multivariate model are included below. When 
adjusting the multivariate model, both, variables that have 
been determined as important in the literature as well as 
variables that measured the participants’ perceived barri-
ers were included in the model. Thus, socioeconomic and 
demographic variables were necessarily included regard-
less of their significance in the bivariate analyses. The 
other included variables served as indicators of accessibil-
ity, availability of drugs, and affordability.
The missing data were imputed 100 times using the 
predictive mean matching method using the “mice” 
package in R 3.1.3. All the regression analyses presented 
below were performed on the imputed datasets separated 
by site, rather than as a complete case analysis. Statistical 
analyses were conducted in R 3.1.3 and MS Excel 2010.
Results
Demographic and socioeconomic characteristics
Among all sites, the majority of households were headed 
by men (Table 1). Overall, 63 % of household heads had 
only a primary school education or less. At least 91 % of 
the participants across all three sites live in mud homes 
and approximately 85 % of residents in all sites own both 
furniture and livestock.
Health‑seeking behaviours
Although at least 80  % of all households surveyed had 
experienced a malaria infection in the family in the past 
year, about 10  % of the participants indicated that they 
take no action upon malaria symptom onset (Table  1). 
In Iguhu and Emutete, approximately 77  % of the resi-
dents sought diagnosis and treatment at hospitals, clinics, 
or dispensaries; fewer than 10  % of the residents sought 
malaria care only at pharmaceutical retailers. However, in 
Emakakha, fewer than 48 % of residents sought diagnosis 
and treatment at a hospital or a clinic and more than 26 % 
of them chose pharmaceutical retailers as their first choice 
of treatment facility. Overall, a sizeable proportion of resi-
dents (40.3–59.4 %) reported delaying seeking care more 
than 24 h after fever onset. The most common reason for 
the delay was a lack of funds, followed by an expectation of 
improvement in condition (Table 1).
In spite of long-standing WHO guidelines recommend-
ing ACT as the first-line treatment for malaria, only 56 % 
of all participants indicated that they used ACT to treat 
malaria. More than 29  % of all respondents indicated 
multiple drugs, including quinine, chloroquine, and 
sulfadoxine-pyrimethamine (SP), as possible options for 
malaria treatment. This suggests an overall propensity for 
choosing treatment based on availability of medication 
rather than on highest degree of efficacy.
Health access measures
Most participants (84  % overall) chose to walk to the 
treatment facility of their choice (Table  1). All par-
ticipants were found to be living less than 1  h of travel 
time from a hospital or clinic (maximum calculated 
time across all sites: 50  min) based on our calculations 
in ArcGIS®. However, patients significantly overesti-
mated the amount of time it would take to walk to the 
nearest facility (paired t test, p  <  0.001). For those who 
reported that the nearest treatment facility was a hospi-
tal or clinic, the self-reported travel time to the hospital 
was overestimated by approximately 22  min in Emutete 
and Iguhu and by over 28  min in Emakakha. For those 
who indicated that the nearest facility was a pharmaceu-
tical retailer, the overestimation of travel time varied by 
site (18 min in Iguhu, 40 min in Emutete, and 33 min in 
Emakakha). Of those who sought care exclusively from 
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Table 1 Socioeconomic and demographic characteristics of study participants in western Kenya highlands
Variable Emakakha (N = 303) Emutete (N = 256) Iguhu (N = 273) Total (N = 832)
Demographic variables
 Primary income earner education
  Did not finish primary 42 (13.9 %) 62 (24.2 %) 75 (27.5 %) 179 (21.5 %)
  Primary school 137 (45.2 %) 114 (44.5 %) 97 (35.5 %) 348 (41.8 %)
  Secondary school and beyond 123 (40.6 %) 79 (30.9 %) 101 (37.0 %) 303 (36.4 %)
  Missing 1 (0.3 %) 1 (0.4 %) 0 2 (0.2 %)
Sex of primary income earner
 Male 236 (77.89 %) 144 (55.9 %) 196 (71.8 %) 576 (69.2 %)
 Female 66 (21.8 %) 107 (41.8 %) 75 (27.5 %) 248 (29.8 %)
 Both sexes 0 2 (0.8 %) 2 (0.7 %) 4 (0.5 %)
 Missing 1 (0.3 %) 5 (3.5 %) 0 6 (0.7 %)
Socioeconomic indicators
 Possessions
  Ownership of both furniture and livestock 268 (88.4 %) 238 (93.0 %) 204 (74.7 %) 710 (85.3 %)
  Ownership of furniture only 29 (9.5 %) 15 (5.8 %) 48 (17.5 %) 92 (11.1 %)
  Ownership of livestock only 2 (0.7 %) 3 (1.2 %) 19 (7.0 %) 24 (2.9 %)
  None 2 (0.7 %) 0 0 2 (0.2 %)
  Missing 2 (0.7 %) 0 2 (0.8 %) 4 (0.5 %)
Home construction
 Mud 276 (91.0 %) 235 (91.8 %) 253 (92.7 %) 764 (91.8 %)
 Cement/brick 22 (7.3 %) 17 (6.6 %) 17 (6.2 %) 56 (6.7 %)
 Missing 5 (1.7 %) 4 (1.6 %) 3 (1.1 %) 12(1.4 %)
Malaria status
 No malaria infection in family in past year 3 (1.0 %) 0 4 (1.5 %) 7 (0.8 %)
 At least one victim in family in past year 291 (96.0 %) 205 (80.1 %) 242(88.6 %) 738 (88.7 %)
 Missing 9 (3.0 %) 51 (19.9 %) 27 (9.9 %) 87 (10.5 %)
Health‑seeking behaviours
 Action taken upon suspicion of malaria
  Treatment sought at hospitals, clinics, and dispensaries exclu‑
sively
144 (47.5 %) 202 (78.9 %) 204 (74.7 %) 550 (66.1 %)
  Treatment sought at pharmaceutical retail facilities exclusively 79 (26.1 %) 16 (6.3 %) 25 (9.2 %) 120 (14.4 %)
  Treatment sought at traditional healers exclusively 1 (0.3 %) 0 0 1 (0.1 %)
  No treatment facility preference indicated 42 (13.9 %) 9 (3.5 %) 25 (9.2 %) 76 (9.1 %)
  No action taken 37 (12.2 %) 24 (9.4 %) 18 (6.6 %) 79 (9.5 %)
  Missing 0 5 (1.9 %) 1 (0.3 %) 6 (0.7 %)
Treatment seeking timeline
 Delay treatment for >24 h after fever onset 180 (59.4 %) 117 (45.7 %) 110 (40.3 %) 407 (48.9 %)
 Seek treatment within 24 h after fever onset 119 (39.3 %) 135 (52.7 %) 160 (58.6 %) 414 (49.8 %)
 Missing 4 (1.3 %) 4 (1.6 %) 3 (1.1 %) 11 (1.3 %)
Medicine
 Artemisinin combination therapy (ACT) exclusively 172 (56.8 %) 149 (58.2 %) 147 (53.9 %) 468 (56.3 %)
 Non‑ACT exclusively: quinine, SP, Fansidar 46 (15.2 %) 16 (6.3 %) 25 (9.2 %) 87 (10.5 %)
 Painkillers exclusively 10 (3.3 %) 6 (2.3 %) 2 (0.7 %) 18 (2.2 %)
 Combination of ACTs, non‑ACT, and painkillers 71 (23.4 %) 80 (31.3 %) 94 (34.4 %) 245 (29.4 %)
 Missing 4 (1.3 %) 5 (1.9 %) 5 (1.8 %) 14 (1.7 %)
Facility where pharmaceutical treatment is purchased
 Hospitals, clinics, and dispensaries exclusively 153 (50.5 %) 188 (73.4 %) 174 (63.7 %) 515 (61.9 %)
 Shopkeepers and chemists exclusively 110 (36.3 %) 24 (9.4 %) 56 (20.5 %) 190 (22.8 %)
 No preference indicated 37 (12.2 %) 41 (16.0 %) 43 (15.8 %) 121 (14.5 %)
 Missing 3 (1.0 %) 3 (1.2 %) 0 6 (0.7 %)
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pharmaceutical retail facilities, 14 % did so despite being 
further away from these facilities than from the nearest 
hospital or clinic.
Risk factor analysis for delay in seeking care
Overwhelmingly, participants who chose to delay seeking 
medical care for more than 24  h after fever onset were 
more likely to visit the pharmaceutical retailer to pur-
chase medication rather than visit the hospital to seek 
diagnostic workup and treatment. This association was 
significant and strongly pronounced across all three sites 
(Table  2). It was reflected in the bivariate analyses and 
stayed significant even after adjustment for other varia-
bles. When all other potentially influential variables were 
accounted for, residents who chose to visit a pharmaceu-
tical retail facility rather than a hospital were more likely 
to delay seeking medical care after the onset of malaria by 
between 121 and 307 % than those who reported choos-
ing a healthcare facility for malaria treatment (Table 3). 
Healthcare facility characteristics
There were fifteen healthcare facilities that served the 
study population. Of the 15, 11 were publicly admin-
istered by the Kenya Ministry of Health and four were 
Table 1 continued
Variable Emakakha (N = 303) Emutete (N = 256) Iguhu (N = 273) Total (N = 832)
Health access measures
 Self‑reported nearest facility
  Hospitals, clinics, and dispensaries exclusively 180 (59.4 %) 227 (88.7 %) 243 (89.0 %) 650 (78.1 %)
  Shopkeepers and chemists exclusively 109 (36.0 %) 16 (6.2 %) 25 (9.1 %) 150 (18.0 %)
  Comparable distance to hospitals/clinics/dispensaries and phar‑
maceutical retail facilities
12 (3.9 %) 12 (4.7 %) 4 (1.5 %) 28 (3.4 %)
  Missing 2 (0.7 %) 1 (0.4 %) 1 (0.4 %) 4 (0.5 %)
GIS‑calculated nearest facility
 Health care center exclusively 93 (30.7 %) 158 (61.7 %) 248 (90.8 %) 499 (60.0 %)
 Pharmaceutical retailer exclusively 209 (69.0 %) 95 (37.1 %) 17 (6.2 %) 321 (38.6 %)
 Equidistant 1 (0.3 %) 3 (1.2 %) 8 (3.0 %) 12 (1.4 %)
Travel time
 Mean self‑reported travel time to nearest facility 54.9 min (95.4 %) 55.1 min (98.0 %) 47.1 min (96.0 %) 52.4 min (96.5 %)
 Missing 14 (4.6 %) 5 (2.0 %) 11 (4.0 %) 30 (3.6 %)
Average GIS‑calculated travel time
 Health care center 32.5 min 25.5 min 27.6 min 85.6 (28.5 %)
 Retailer 21.9 min 27.0 min 57.6 min 106.5 (35.5 %)
Method of travel
 Walk exclusively 260 (85.8 %) 200 (78.1 %) 240 (87.9 %) 700 (84.1 %)
 Bicycle 30 (9.9 %) 16 (6.2 %) 10 (3.7 %) 56 (6.7 %)
 Car or other motorized transport 8 (2.6 %) 25 (9.8 %) 10 (3.7 %) 43 (5.2 %)
 Mix of walking, biking, and motorized transport 3 (1.0 %) 12 (4.7 %) 11 (4.0 %) 26 (3.1 %)
 Missing 2 (0.7 %) 3 (1.2 %) 2 (0.7 %) 7 (0.8 %)
Reason for delay (if any)
 Do not delay 2 (0.7 %) 0 1 (0.4 %) 3 (0.4 %)
 Money 182 (60.0 %) 98 (38.3 %) 89 (32.6 %) 369 (44.4 %)
 Distance 2 (0.7 %) 2 (0.8 %) 1 (0.4 %) 5 (0.6 %)
 Expect improvement of condition 46 (15.2 %) 50 (19.5 %) 33 (12.1 %) 129 (15.5 %)
 Transportation 1 (0.3 %) 0 1 (0.4 %) 2 (0.2 %)
 Mix 15 (4.9 %) 1 (0.4 %) 5 (2.1 %) 21 (2.5 %)
 Other 0 0 1 (0.4 %) 1 (0.1 %)
 Missing 55 (18.2 %) 105 (41.0 %) 142 (52.0 %) 302 (36.3 %)
Affordability of treatment
 Found treatment unaffordable 43 (14.2 %) 85 (33.2 %) 99 (36.3 %) 227 (27.3 %)
 Found treatment affordable 245 (80.8 %) 169 (66.0 %) 174 (63.7 %) 588 (70.7 %)
 Missing 15 (5.0 %) 2 (7.8 %) 0 17 (2.0 %)
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privately owned and operated (Table  4). It was found 
that 40 % of them exhausted their stores of artemisinin-
based malaria treatment at least one or more times per 
month; six out of the 15 encountered a shortage more 
frequently. Furthermore, the average cost to patients per 
visit for malaria treatment at a public facility was 72 KES 
(equivalent to $0.90 US at the time) and 125 KES ($1.56 
US) at a private facility. The costs were reflective of the 
admission or registration fees, diagnosis fees, and other 
miscellaneous charges. These charges did not include the 
cost of the subsidized ACT drugs (40 KES, $0.50 US, to 
be paid for by the patient) bringing the average total cost 
Table 3 Multivariate (adjusted) model of relevant risk factors for odds of delaying treatment ≥24 h by study site
Significant at α <0.05 
OR odds ratio, CI confidence interval
Variables Emakakha OR [95 % CI] Emutete OR [95 % CI] Iguhu OR [95 % CI]
Lived in mud home 8.32 [2.58, 26.90] 2.75 [0.78, 9.74] 2.39 [0.60, 9.61]
Ref: lives in cement/brick home 1 1 1
Owned either furniture or livestock or neither 0.98 [0.42, 2.27] 0.88 [0.31, 2.55] 0.65 [0.34, 1.26]
Ref: owns both furniture and livestock 1 1 1
Wage head has a primary school education 0.82 [0.46, 1.47] 1.60 [0.82, 3.14] 0.94 [0.49, 1.79]
Wage head did not finish primary school 0.45 [0.20, 1.03] 1.46 [0.67, 3.21] 0.99 [0.49, 1.99]
Ref: wage head finished secondary school or beyond 1 1 1
Female wage head of household 1.29 [0.68, 2.45] 1.69 [0.96, 3.0] 3.13 [1.72, 5.69]
Ref: male wage head of household 1 1 1
Chose pharmaceutical retailers for treatment 4.07 [2.31,7.21] 2.21 [1.07, 4.61] 2.60 [1.35, 4.99]
Ref: Chose healthcare facility for treatment 1 1 1
Self‑reported nearest treatment facility is pharmaceutical retailer 1.37 [0.76, 2.49] 4.23 [1.55, 11.53] 0.15 [0.04, 0.48]
Ref: self‑reported nearest facility was a healthcare facility 1 1 1
Walked to facility when seeking treatment 1.10 [0.5, 2.42] 0.48 [0.24, 0.95] 1.91 [0.76, 4.81]
Ref: took a car or other motorized transport to facility when seeking treatment 1 1 1
Found treatment to be unaffordable 5.36 [2.24, 12.81] 1.15 [0.64, 2.06] 0.59 [0.33, 1.06]
Did not find treatment to be unaffordable 1 1 1
Table 2 Bivariate analyses of relevant risk factors for odds of delaying treatment ≥ 24 h by study site
SSgnificant at α <0.0
OR odds ratio, CI confidence interval
Variable Emakakha OR [95 % CI] Emutete OR [95 % CI] Iguhu OR [95 % CI]
Lived in mud home 4.21 [1.60, 11.04] 3.02 [0.96, 9.52] 3.42 [0.95, 12.2]
Ref: lives in cement/brick home 1 1 1
Owned either furniture or livestock or neither 0.77 [0.37, 1.60] 0.81 [0.30, 2.21] 0.79 [0.45, 1.41]
Ref: owns both furniture and livestock 1 1 1
Wage head has a primary school education 0.98 [0.59, 1.63] 1.89 [1.04, 3.42] 1.03 [0.58, 1.83]
Wage head did not finish primary school 0.63 [0.31, 1.27] 1.65 [0.83, 3.26] 1.45 [0.79, 2.67]
Ref: wage head finished secondary school or beyond 1 1 1
Female wage head of household 1.34 [0.76, 2.36] 1.63 [0.98, 2.72] 3.41 [1.96, 5.94]
Ref: male wage head of household 1 1 1
Chose pharmaceutical retailers for treatment 3.86 [2.36, 6.30] 2.79 [1.42, 5.50] 1.86 [1.06, 3.28]
Ref: chose healthcare facility for treatment 1 1 1
Self‑reported nearest facility was a pharmaceutical retailer 2.12 [1.30, 3.45] 5.05 [1.97, 12.93] 0.20 [0.07, 0.59]
Ref: self‑reported nearest facility was a healthcare facility 1 1 1
Walked to facility when seeking treatment 1.11 [0.57, 2.18] 0.59 [0.32, 1.08] 2.24 [0.96, 5.21]
Ref: took a car or other motorized transport to facility when seeking treatment 1 1 1
Found treatment to be unaffordable 2.64 [1.31, 5.31] 1.28 [0.76, 2.16] 0.56 [0.33, 0.95]
Did not find treatment to be unaffordable 1 1 1
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per patient per visit up to 112 KES ($1.40 US) for pub-
lic facilities that did not have ACT in stock and 165 KES 
($2.06 US) for private facilities.
Most of the facilities (12) used microscopy in com-
bination with other diagnosing methods to determine 
infection status as recommended by the WHO; however, 
three of the health facilities treated patients based on 
clinical presentation only. Of the 15 clinics and hospitals, 
11 (ten public and one private) received their drug sup-
ply directly from Kenya Medical Supplies Authority, the 
medical logistics provider for all Ministry of Medical Ser-
vices/Public Health supported healthcare facilities in the 
country. Two private facilities purchased directly from 
the manufacturer and two others (one private and one 
public) purchased their ACT stock from local retailers.
Pharmaceutical retail facility characteristics
Of the 135 pharmaceutical retail facilities inter-
viewed for the study, only nineteen were operated by a 
licensed chemist or pharmacist. The remaining facili-
ties were operated by small business owners who ran 
shops in the local markets or along the roadsides. All 
19 licensed chemists or pharmacists had anti-malari-
als available for sale in their facility on the day of the 
interview. However, only 49 of the 116 non-licensed 
retailers were found to sell any kind of anti-malarial 
therapy. Of those 49, only 16 reported the presence of 
ACT in stock. The remainder sold SP drugs, amodi-
aquine, quinine, and pain medications. The most com-
monly stocked antimalarial among the non-licensed 
retailers were SP drugs; twenty-two shops carried a 
Table 4 Summary of health care facility (hospitals, clinics, and dispensaries) surveyed
Variable Public Private
Number of facilities surveyed 11 (73.3 %) 4 (26.7 %)
 # of hospitals 3 (20.0 %) 1 (6.7 %)
 # of health centres 5 (33.3 %) 2 (13.3 %)
 # of dispensaries/clinics 3 (20.0 %) 1 (6.7 %)
Hours of operation
 9 h or fewer 7 (46.6 %) 4 (26.7 %)
 24 h 4 (26.7 %) 0
Days of operation
 5 days/week 5 (33.3 %) 1 (7.0 %)
 7 days/week 6 (40.0 %) 3 (20.0 %)
 Median population served [range] 13,885 [1310–164,951] 11,189 [2683–20,000]
Staffing
 # of facilities with doctors [range] 2 (13.3 %) [0–8] 1 (7.0 %) [0–3]
 Median number of clinical officers [range] 2 [0–18] 1.5 [0–4]
 Median number of nurses [range] 8 [2–53] 7 [2–20]
 Median number of microscopists [range] 2 [0–4] 2 [2–4]
Malaria
 Median # of microscopy confirmed cases in three mos. preceding survey [range] 222 189
 Diagnostic method: microscopy exclusively 5 (33.3 %) 2 (13.3 %)
 Diagnostic method: microscopy + RDT 3 (20.0 %) 2 (13.3 %)
 Diagnostic method: symptoms exclusively 3 (20.0 %) 0
ACT stocking
 Facilities stocked with ACT at time of survey 11 (73.3 %) 4 (26.7 %)
 Experienced shortage of ACT in 3 months preceding survey [range] 4 (26.7 %) 2 (13.3 %)
 # of facilities that had to wait >24 h before ACT was restocked 4 (26.7 %) 2 (13.3 %)
 # of facilities that either substitute another anti‑malarial or refer patient to nearest retailer 5 (33.3 %) 2 (13.3 %)
Charges [in Kenyan shillings]
 # of facilities that charged registration fees [average fee] 11 (73.3 %) [19 KSH] 3 (20.0 %) [55 KSH]
 # of facilities that charged diagnosis fees [average fee] 8 (53.3 %) [46 KSH] 4 (26.6 %) [70 KSH]
 # of facilities that charged other miscellaneous fees per patient per visit [average fee] 8 (53.3 %) [26 KSH] 0
 # of facilities that charged for medication [average fee] 1 (6.7 %) [40 KSH] 3 (20.0 %) [73 KSH]
 Overall average costs per patient of health care facility visit (not including cost of medication) 
[range]
72 KSH [30 KSH–90 KSH] 125 KSH [50 KSH–250 KSH]
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variety of SP brands. Nine sold amodiaquine and five 
stocked quinine, either individually or in combination 
with other therapies. Of all 135 retailers, 38 % served 
100 or more customers per day.
The surveys of retailers also served as an opportunity 
to test for the presence of counterfeit or substandard 
artemisinin-based anti-malarial drugs in the study sites. 
Survey staff purchased and tested samples of AL/Coar-
tem® from a random selection of eight retailers and phar-
macies associated with healthcare facilities and further 
testing found that all samples contained the manufacture 
labelled amount of the artemisinin-derived active com-
pound (Additional file 2), suggesting the quality of ACT 
being sold met the standard requirements.
Discussion
Timely and appropriate case management of malaria is 
integral to the reduction of disease-associated morbidity 
and mortality. An improvement in the understanding of 
treatment-seeking behaviours in the susceptible popula-
tions can enable the development of targeted interven-
tions that are designed in a manner that is feasible and 
sustainable within individual communities. However, in 
spite of intensive interventions in the area, the determi-
nants of treatment-seeking behaviours in our study pop-
ulation have been poorly described.
The results of the current study concur with existing 
literature to show that medical facilities are largely the 
primary source of malaria care after fever onset [13]. 
However, the pharmaceutical retailers are a dominant 
player in the system and need to be considered as an 
important variable in any future interventions. Further-
more, the subsidies for ACT provided by the government 
may be masking the high cost of care imposed by medical 
facilities, thus driving patients towards cheaper alterna-
tives or to delay seeking care altogether.
The results show a strong association between treat-
ment-seeking delay and choosing to seek treatment at a 
pharmaceutical retailer rather than visiting a health care 
facility. This association is significant and present in all 
sites and holds even after adjustment for other variables. 
This may be reflective of a reduced perception of sever-
ity of malaria that has been shown to occur in areas of 
medium to high malaria endemicity [23]. Combined 
with other barriers such as availability of drugs and costs 
associated with a hospital visit, the low level of perceived 
severity may be a strong contributor to delaying care.
It was expected that travel time would be a strong bar-
rier of access to medical care in the study population. 
However, among the participants who responded to the 
survey regarding their reasons for delaying treatment, 
a lack of funds stood out as the primary response. Yet, 
the regression analyses did not show a clear association 
between delaying treatment and self-reported affordabil-
ity across the three sites. This may be due to a discrep-
ancy in the participants’ interpretation of affordability 
based on our survey and the intention of the survey ques-
tion. Participants may have delayed seeking care at the 
time of malaria symptom onset because they did not have 
sufficient funds. However, at the time when they chose 
to seek treatment, they may have procured the necessary 
funds and thus, their perception of affordability would 
have shifted.
Furthermore, the travel time derived for this study, 
though an improvement upon measures using Euclidean 
distance, cannot account for the variety of factors that 
may influence a person’s estimation of the travel time 
from their home to the nearest healthcare facility. These 
factors may include road conditions (which vary with the 
seasons), the ability to gather sufficient funds, preparing 
oneself or child for travel, and procuring transportation. 
These estimates, along with other self-reported variables 
were also susceptible to recall bias, as is the case with 
many survey-based studies. However, a diligent attempt 
was made to glean a representative sample of the area by 
using an appropriate sample size in each site and by ran-
domizing the selection of participants from within the 
pre-defined areas.
Since surveys of the healthcare facilities indicated that 
the average cost of a malaria-related visit is between 112 
and 165 KES (including the cost of medication), it is clear 
that is there is discordance in the original intention of the 
subsidization policy and its implementation. While ACT 
at government-run facilities was meant to be provided 
for free to the patient, the frequent stock-outs led the 
facilities surveyed to refer patients elsewhere, including 
to private retailers, where the patients may face a greater 
likelihood of receiving a less effective anti-malarial. Pri-
vate retailers are not always bound by the subsidization 
policy and charge for ACT at a higher rate than 40 KES 
[24]. The ubiquity of various anti-malarial drugs in the 
market combined with the high charges associated with a 
hospital or clinic visit may also serve to reduce a patient’s 
perceived need for a full diagnostic workup.
Accessibility is an important determinant of treatment-
seeking behaviour and has implications for the contin-
ued transmission of malaria. Some of the variation in 
health-seeking behaviours between the three study sites 
may be attributed to the lack of paved roads in the area 
and the hilly terrain, neither of which are conducive to 
motor access (see Fig. 1). Most of the participants did not 
live along major roads. The perceived benefits of receiv-
ing a proper malaria diagnosis from a healthcare facility 
may not be sufficient to outweigh the perceived cost of 
travel, in terms of both time and effort. Finally, there is 
a stark difference between the low number of healthcare 
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facilities located in Emakakha and how many more are 
located in the other two study sites; there is one dispen-
sary and one health centre located within the boundaries 
of Emakakha and another health centre that lies between 
the boundaries of Emakakha and Emutete. However, 
there are several retailers lining the major road that 
bisects the Emakakha study area, which may help explain 
why more than one-third of the residents in the site 
reported a retailer as the nearest treatment facility.
As was observed in the study by Sumba et al., the par-
ticipants’ decision to seek treatment at a healthcare 
facility within 24  h of fever onset was not significantly 
correlated with their socioeconomic status, education 
level, or proximity to the facility [13]. The strongest 
determining factor of delay was the decision to choose 
to seek treatment at a pharmaceutical retailer rather than 
a medical facility. As such, the observed propensity of 
the pharmaceutical retailers as seen in other studies [11, 
25] to sell medication without appropriate anti-malarial 
properties has serious negative implications for malaria 
control and the potential for the spread of artemisinin 
resistance. A previous experience of being referred to a 
pharmaceutical retailer when the healthcare facility had 
depleted its ACT stock may also deter patients from 
making future visits to the healthcare facility; they may 
choose to go directly to the retailer, seeing it as a cheaper, 
faster, and quicker alternative. Future interventions must 
recognize and include retailers as key players in any con-
trol or elimination programme that is to be implemented.
Conclusion
The year 2010 was the first year that the Affordable 
Medicines Facility-malaria program to subsidize ACT at 
private retailers was implemented with the intention of 
reducing the cost of ACT to 40 KES (equivalent to $0.50 
at the time) around the country [26, 27]. However, the 
discrepancy between the cost of the drug and the full cost 
of a hospital visit for malaria care was large and posed a 
significant burden to the affected population. A consid-
eration of change in policy may be needed if the impact 
is to be significant. These changes may include the imple-
mentation of a flat fee for all malaria diagnoses and treat-
ments at public hospitals or an increase in the subsidy of 
the drug to offset the costs of seeking care at a medical 
facility. The high cost of seeking diagnosis and treatment 
at a healthcare facility with appropriate diagnosis may 
be inhibiting positive health-seeking behaviour and may 
have a significant impact on the progress of malaria elim-
ination in the area, inadvertently fueling the development 
and spread of drug resistant parasite strains.
Another point of concern is the relationship between 
the local health facilities and the pharmaceutical retail 
outlets. Some facilities not only refer their patients to 
nearby retailers when ACT is not available in the facil-
ity but also indicated that they occasionally receive their 
supply of ACT from these retailers. Unearthing such 
relationships can help reveal weak points in control and 
elimination programmes and allow for the development 
of directed improvement measures.
Understanding the local health behaviours that perpet-
uate transmission of malaria will help develop targeted 
preventive measures, as well as to develop educational 
interventions that can empower the residents with the 
knowledge needed to combat malaria in a safe and effec-
tive manner. Ensuring patient access to health care facili-
ties in countries with high disease burdens has broader 
implications on measures of equity and on public health 
prevention methodologies. It is hoped that the results 
of this study begin to fill in the gaps in knowledge that 
would be required to implement policy changes and 
improve access to health care facilities for the people of 
the western Kenyan highlands and others in areas experi-
encing similar malaria transmission patterns.
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